PROGRESS IN TARGETING THERAPY IN UVEAL MELANOMA

ADDING  INTERFERON WOULD MAKE MORE SENSE THAN ADDING AVASTIN TO SIROLIMUS IN UVEAL MELANOMA.

Uveal Melanoma has been now extensively studied and has been associated in up to 50% of cases, to GNAQ/GNA11 genes, these is basically a G-protein, a switch that stays on in patient amplifying permanently the MAPK pathways, and therefore the MTOR.  This fact amplifies the role of MTOR inhibitors in this disease's treatment.
Although Avastin could have a role by involving another target, it seems that intervening at epigenic level by using Dasatinib or by using a known effective agent such as interferon would add more.  The caveat here is that epigenic intervention could tamper with MTOR expression proper and Mitigate the role of its inhibitor.  Suffice is to say that intervention at epigenic level could prove additive to MTOR inhibitors.   It is still to be established whether purified Hamartin, a derivative from TCS1 gene (in combination or not with Tuberin-TSC2) may prove  synergestic to MTOR inhibitors...